Quaser Machine Tools Inc. (4563)

Overview

AnGes, Inc. is a biopharmaceutical company founded in 1999, focusing on the research and development of gene-based medical therapies. Originally known as AnGes MG, Inc., the company underwent a name change to AnGes, Inc. in July 2017. With its headquarters in Ibaraki, Japan, AnGes is at the forefront of developing innovative solutions for a range of diseases by leveraging gene therapy and nucleic acid medicines. Its core research and collaborative efforts with prestigious institutions like Osaka University underscore its commitment to addressing unmet medical needs.

Products and Services

AnGes, Inc. offers a variety of products and services aimed at combating a range of diseases through cutting-edge gene therapy and nucleic acid technology. Below is a detailed look at their key developments:

• Hepatocyte Growth Factor (HGF) Plasmid: This is AnGes's lead product, a gene therapy focused on the treatment of ischemic diseases. It represents a groundbreaking approach in the field of regenerative medicine, aiming to improve blood flow and encourage tissue repair in affected areas.
• NF-kB Decoy Oligonucleotide: This nucleic acid medicine is designed to suppress inflammation, offering a novel treatment option for conditions associated with chronic inflammation, including low back pain. By targeting the NF-kB pathway, it prevents the transcription of genes involved in inflammation.
• Atopic Dermatitis and Asthma Treatments: The company is also exploring drugs targeting atopic dermatitis and asthma, reinforcing its commitment to providing solutions for inflammatory and allergic conditions.
• Medical Devices for Vascular Medicine: AnGes is developing medical devices aimed at the prevention and treatment of vascular diseases, indicating a multidisciplinary approach to treating circulatory system disorders.
• Cervical Intraepithelial Neoplasia (CIN) Therapeutic Vaccines for Cervical Cancer: Another significant area of research is the development of therapeutic vaccines aimed at treating CIN to prevent cervical cancer. This approach represents a potential shift towards more preventive strategies in oncology.
• DNA Vaccines for High Blood Pressure: In collaboration with Osaka University, AnGes is working on DNA vaccines targeting high blood pressure, a common but serious condition that can lead to cardiovascular diseases if untreated.